Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov official registry

Prostate Carcinoma Metastatic in the Bone clinical trials

Every US clinical trial registered for Prostate Carcinoma Metastatic in the Bone — phase mix, recruiting status, and the sponsors running them, straight from the NIH ClinicalTrials.gov registry.

7 US clinical trials ·

The research picture

Prostate Carcinoma Metastatic in the Bone has 7 registered US clinical trials; none are currently listed as recruiting, so most are completed or in follow-up.

0
recruiting participants now
0%
of trials open to enrollment
0
in Phase 3–4 (later-stage)
3
top sponsor: M.D. Anderson Cancer Center

Counts reflect the public ClinicalTrials.gov registry as last mirrored by PlainTrial. Status and phase are reported by each study's sponsor. This is reference information, not medical advice.

Active & Recent Trials

ACTIVE NOT RECRUITING Phase 2 223 participants

Abiraterone Acetate and Antiandrogen Therapy With or Without Cabazitaxel and Prednisone in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer Previously Treated With Docetaxel

ECOG-ACRIN Cancer Research Group

NCT03419234

ACTIVE NOT RECRUITING Phase 1 173 participants

Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies

M.D. Anderson Cancer Center

NCT03217747

ACTIVE NOT RECRUITING Phase 2 60 participants

Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer

M.D. Anderson Cancer Center

NCT03821792

ACTIVE NOT RECRUITING Phase 2 60 participants

Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord

M.D. Anderson Cancer Center

NCT02713269

ACTIVE NOT RECRUITING Phase 2 30 participants

Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer

University of Southern California

NCT03344211

ACTIVE NOT RECRUITING Phase 1 15 participants

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

Jonsson Comprehensive Cancer Center

NCT03582475

COMPLETED Phase 2 14 participants

Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway

University of Washington

NCT02598895

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 5

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Reading the Prostate Carcinoma Metastatic in the Bone Trial Landscape

ClinicalTrials.gov lists 7 US studies indexed under Prostate Carcinoma Metastatic in the Bone, and 0 of those are currently open to recruitment — roughly 0% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.

The phase distribution for Prostate Carcinoma Metastatic in the Bone shows 0 late-stage studies (Phase 3 and Phase 4 combined) alongside 7 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.

Top sponsor activity for Prostate Carcinoma Metastatic in the Bone is led by M.D. Anderson Cancer Center with 3 indexed trials, alongside 4 other organizations in the top contributor list. The list on this page surfaces up to 7 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.

Frequently Asked Questions

How many clinical trials are there for Prostate Carcinoma Metastatic in the Bone?

PlainTrial tracks 7 US clinical trials for Prostate Carcinoma Metastatic in the Bone, of which 0 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Prostate Carcinoma Metastatic in the Bone?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Related

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →